DGAP-News: STRATEC - Growth trajectory confirmed after first six months of 2011
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Regulatory Approval
STRATEC - Growth trajectory confirmed after first six months of 2011
27.07.2011 / 07:46
---------------------------------------------------------------------
STRATEC - Growth trajectory confirmed after first six months of 2011
- Sales of EUR 48.5 million in Q1-Q2/2011
(+12.5%; Q1-Q2/2010: EUR 43.1 million)
- EBIT margin increased to 18.7% in Q1-Q2/2011,
up from 18.0% in Q1/2011(Q1-Q2/2010: 18.7%)
- Consolidated net income of EUR 7.0 million in Q1-Q2/2011
(+14.8%; Q1-Q2/2010: EUR 6.1 million)
- Earnings per share of EUR 0.60 in Q1-Q2/2011
(+13.2%; Q1-Q2/2010: EUR 0.53)
Birkenfeld, July 27, 2011
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
announced its figures for the period from January 1, 2011 to June 30, 2011
upon the publication of its interim report as of June 30, 2011.
Key figures (EUR 000s) 01.01.- 01.01.- ChangeFinancial performance
06.30.2011 06.30.2010
Sales 48,515 43,140 +12.5%
Overall performance 54,800 48,821 +12.3%
EBITDA 10,750 9,472 +13.5%
EBIT 9,078 8,056 +12.7%
Consolidated net income 6,964 6,069 +14.8%
Earnings per share (EUR) 0.60 0.53 +13.2%
EBIT margin (%) 18.7% 18.7%
Sales for the first six months of 2011 grew year-on-year by 12.5% from EUR
43.1 million to EUR 48.5 million. Second-quarter sales rose to EUR 26.4
million, up 19.2% compared with the first quarter of 2011. STRATEC expects
its sales performance to accelerate further over the balance of 2011,
driven by recent market launches of new analyzer systems by our partners.
This expectation has been confirmed by the performance in the first two
quarters of the year and gives STRATEC confidence to reiterate its forecast
guidance for 2011. Accordingly, the company continues to expect 2011 sales
to be in a range of EUR 114 million to EUR 123 million at an EBIT margin of
at least 18.5%.
The unwinding of the remaining consumable backlog from the fourth quarter
of 2010 has led to a rise in the proportion of sales generated by
consumables, resulting in a slightly higher increase in the EBIT margin
than originally expected. The EBIT margin rose to 18.7% in the first six
months, up from 18.0% in the first quarter of 2011.
Consolidated net income increased year-on-year by 14.8% to EUR 7.0 million,
and earnings per share increased to EUR 0.60.
Project development
The numerous systems in development and scheduled for market launch in the
coming years are progressing on schedule. For two of these systems,
manufacturing capacities are currently being increased for serial
production.
Of the three new contracts expected in 2011, one new development and supply
contract has been signed. Additional negotiations are in advanced stages
and provide the grounds for us to confirm our previous forecast. Further
details concerning these contracts will be published once agreements have
been reached with the respective customers.
Other developments
STRATEC can report a slightly above-budget overall business performance for
the first half of 2011, and one accompanied by an unaltered positive
business outlook. This is despite a renewed increase in macroeconomics
concerns on the global economy.
To date, we have experienced no negative impacts from government savings
measures or from fiscal policy measures in the euro and US dollar areas on
our customers' planned acceptance volumes. Indeed, STRATEC's business model
remains largely independent of macroeconomic factors. Furthermore and as
previously announced, STRATEC has not witnessed any supplier problems seen
in other industries in the wake of the Japanese earthquake crisis.
Development in staff totals
Including temporary employees, the STRATEC Group had a total workforce of
466 employees as of June 30, 2011 (June 30, 2010: 399). Compared with March
31, 2011, the workforce has risen by a further 14 employees. This
substantial year-on-year increase in staff totals is mainly due to the
takeover of STRATEC Biomedical USA (formerly Ballista Inc.) as of July 1,
2010. The personnel expenses relevant in this context are not expected to
show any further comparable increase.
Outlook
STRATEC continues to expect accelerated sales growth in the remainder of
the 2011 financial year. Specifically, the company expects to generate
sales in a range of EUR 114 million to EUR 123 million in 2011. Based on
sales in the 2010 financial year, the STRATEC Group expects to achieve
average sales growth (CAGR) of at least 17.0% over the financial years 2011
to 2013. Consistent with these expectations, the EBIT margin should amount
to at least 18.5% in 2011, and to at least 19.0% in the two subsequent
years.
Achievement of or potentially exceeding the upper end of sales guidance
(EUR 123 million) in 2011 is dependent on the timing of the planned and
pending market launches of new systems, which is also determined by their
approval in the relevant markets.
Further details can be found in our Interim Report as of June 30, 2011
published at www.stratec.com>Investor Relations>IR News>Financial
Reports.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany,
the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
27.07.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.comInternet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
133309 27.07.2011
Datum: 27.07.2011 - 07:46 Uhr
Sprache: Deutsch
News-ID 34688
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC - Growth trajectory confirmed after first six months of 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
